Information Provided By: 
Fly News Breaks for April 29, 2016
BMY
Apr 29, 2016 | 08:10 EDT
UBS raised its price target on Bristol-Myers to $80 from $73 following Q1 results. The firm cited the company's raised guidance and said the stock remains their favorite high expectations, high multiple, large cap name based on its strong IO franchise and expected operating leverage over the next few years. UBS reiterated its Buy rating on Bristol-Myers shares.
News For BMY From the Last 2 Days
